(Source: Business Wire)
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which
acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced
the election of Bernhard Hampl, Ph.D. to its Board of Directors
effective November 1, 2009. Dr. Hampl, also named as Executive Chairman
of the Board, succeeds current Chairman Dr. Ulf M. Schneider. Dr.
Schneider will continue to serve on the Board of Directors and as a
member of the Audit Committee.
"Dr. Hampl is one of the most experienced and well-respected leaders in
the generic pharmaceutical industry. His addition to the Board both
strengthens and broadens the depth of our industry expertise," said Dr.
Schneider. "I am confident that Dr. Hampl is the right person to serve
as Executive Chairman and know that he has the strategic and operational
leadership experience that will allow us to capitalize on the
opportunities before us."
"I have been fortunate to have worked extensively in the generic
pharmaceutical field and have witnessed many changes within our
industry. I am pleased to be joining the Board of Fresenius Kabi
Pharmaceuticals Holding and look forward to using my experience to
expand APP's pipeline, while exploring new opportunities that will
position it for future growth," said Dr. Hampl.
Dr. Hampl also serves as a member of the Board of Directors of
ChemWerth, Inc., a private corporation, and as an advisor to Advent
International Corporation, Farmhispania and Guidepoint Global.
During his notable career, Dr. Hampl worked for 15 years for Cyanamid
GmbH and its business units, Lederle and Durachemie GmbH, where he held
positions as Director, Research and Development, Technical Director and
Plant Director. In 1995, Dr. Hampl joined Hexal AG, a leading
manufacturer and marketer of generic pharmaceuticals in Germany, and led
business development opportunities in the U.S. generics market. In
October 1995, Hexal acquired 50 percent of Eon Labs, Inc., and 100
percent ownership in 2000. During this time, Dr. Hampl served as
President and CEO. In July 2005, Sandoz, Inc., a division of Novartis
AG, completed its merger with Eon Labs and Dr. Hampl became the
President and Chief Executive Officer of Sandoz, Inc., the U.S.
operating unit of Sandoz. He resigned from Sandoz effective September
30, 2008. While CEO of Sandoz, Dr. Hampl also served as a member of the
Executive Board of the Generic Pharmaceutical Association. He received
his Ph.D. in pharmaceutical chemistry from Ludwig-Maximillians
University in Munich, Germany.
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc.
